$21.09
1.63% day before yesterday
Nasdaq, Dec 27, 10:16 pm CET
ISIN
US14167L1035
Symbol
CDNA
Sector
Industry

CareDx, Inc. Stock price

$21.09
-3.82 15.34% 1M
+6.70 46.56% 6M
+9.09 75.75% YTD
+8.39 66.06% 1Y
-23.03 52.20% 3Y
-0.36 1.68% 5Y
+14.06 200.00% 10Y
Nasdaq, Closing price Fri, Dec 27 2024
-0.35 1.63%
ISIN
US14167L1035
Symbol
CDNA
Sector
Industry

Key metrics

Market capitalization $1.13b
Enterprise Value $920.26m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 754.31
EV/Sales (TTM) EV/Sales 2.94
P/S ratio (TTM) P/S ratio 3.62
P/B ratio (TTM) P/B ratio 4.10
Revenue growth (TTM) Revenue growth 5.26%
Revenue (TTM) Revenue $312.78m
EBIT (operating result TTM) EBIT $-57.72m
Free Cash Flow (TTM) Free Cash Flow $1.22m
Cash position $240.85m
EPS (TTM) EPS $-2.70
P/E forward negative
P/S forward 3.44
EV/Sales forward 2.80
Short interest 8.21%
Show more

Is CareDx, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

CareDx, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a CareDx, Inc. forecast:

5x Buy
56%
3x Hold
33%
1x Sell
11%

Analyst Opinions

9 Analysts have issued a CareDx, Inc. forecast:

Buy
56%
Hold
33%
Sell
11%

Financial data from CareDx, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
313 313
5% 5%
100%
- Direct Costs 110 110
1% 1%
35%
203 203
8% 8%
65%
- Selling and Administrative Expenses 169 169
7% 7%
54%
- Research and Development Expense 74 74
15% 15%
24%
-40 -40
51% 51%
-13%
- Depreciation and Amortization 18 18
4% 4%
6%
EBIT (Operating Income) EBIT -58 -58
42% 42%
-18%
Net Profit -144 -144
59% 59%
-46%

In millions USD.

Don't miss a Thing! We will send you all news about CareDx, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

CareDx, Inc. Stock News

Positive
Seeking Alpha
4 days ago
CareDx is a promising candidate for the Bioreactor growth portfolio due to its leadership in transplant diagnostics and significant growth potential despite previous concerns. The company has shown strong revenue growth, with Q3 2023 revenue up 23% YoY, and maintains a robust balance sheet with $241M in cash and no debt. Key risks include potential slow adoption by transplant centers, competiti...
Neutral
Business Wire
11 days ago
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) - The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers — today announced that the company will participate in the upcoming 43rd Annual J.P. Morgan Healthcare Conf...
Neutral
Business Wire
18 days ago
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that CareDx will partner with TC BioPharm to perform pharmacokinetic analysis using its A...
More CareDx, Inc. News

Company Profile

CareDx, Inc. operates as a transplant diagnostics company,which discovers, develops, and commercializes diagnostic solutions. Its product includes AlloMap, AlloSure, and Laboratory products. The company was founded on December 21, 1998 and is headquartered in Brisbane, CA.

Head office United States
CEO John Hanna
Employees 643
Founded 1998
Website www.caredx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today